BUZZ-Unicycive rises as FDA accepts resubmitted filing for kidney drug** Shares of drug developer Unicycive Therapeutics UNCY.O rise 9.5% to $7.69 premarket
** Co says FDA accepted for review its resubmitted application for oxylanthanum carbonate, a pill for high phosphate levels in dialysis patients
** High phosphate levels occur in people with late‑stage kidney disease when the body cannot remove excess minerals, per co
** Co says FDA raised no initial concerns on safety or effectiveness; decision expected by June 27
** UNCY's drug aims to cut pill burden to help patients stay on treatment; possible launch later this year if approved, co says
** Shares down ~27% in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments